- Home
- LCTX vs AVIR Comparison
LCTX vs AVIR Comparison
Compare LCTX & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- AVIR
- Stock Information
- Founded
- LCTX 1990
- AVIR 2012
- Country
- LCTX United States
- AVIR United States
- Employees
- LCTX N/A
- AVIR N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- LCTX Health Care
- AVIR Health Care
- Exchange
- LCTX Nasdaq
- AVIR Nasdaq
- Market Cap
- LCTX 274.0M
- AVIR 290.4M
- IPO Year
- LCTX N/A
- AVIR 2020
- Fundamental
- Price
- LCTX $1.21
- AVIR $3.49
- Analyst Decision
- LCTX Strong Buy
- AVIR Hold
- Analyst Count
- LCTX 4
- AVIR 1
- Target Price
- LCTX $4.25
- AVIR $6.00
- AVG Volume (30 Days)
- LCTX 1.5M
- AVIR 335.8K
- Earning Date
- LCTX 08-12-2025
- AVIR 08-07-2025
- Dividend Yield
- LCTX N/A
- AVIR N/A
- EPS Growth
- LCTX N/A
- AVIR N/A
- EPS
- LCTX N/A
- AVIR N/A
- Revenue
- LCTX $10,914,000.00
- AVIR N/A
- Revenue This Year
- LCTX N/A
- AVIR N/A
- Revenue Next Year
- LCTX $178.80
- AVIR N/A
- P/E Ratio
- LCTX N/A
- AVIR N/A
- Revenue Growth
- LCTX 76.43
- AVIR N/A
- 52 Week Low
- LCTX $0.37
- AVIR $2.46
- 52 Week High
- LCTX $1.31
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- LCTX 59.58
- AVIR 49.33
- Support Level
- LCTX $1.15
- AVIR $3.45
- Resistance Level
- LCTX $1.31
- AVIR $3.86
- Average True Range (ATR)
- LCTX 0.08
- AVIR 0.13
- MACD
- LCTX 0.01
- AVIR 0.01
- Stochastic Oscillator
- LCTX 70.59
- AVIR 39.62
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).